Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
A weight loss drug developer's stock soars
BioAge Labs IPO: Stock price will be closely watched today as the obesity drug developer debuts on the Nasdaq
The California-based biotech priced its shares at $18. Its lead product, a weight loss treatment called Azelaprag, is still in clinical trials. BioAge Labs is having its initial public offering today.
A weight loss drug developer's stock soars after a $198 million IPO
Shares of BioAge Labs (BIOA), a biopharmaceutical company focused on obesity drugs, opened 25% above its initial public offering (IPO) price on Thursday.
Weight-loss drug developer BioAge raises $198 million in U.S. IPO
(Reuters) -BioAge Labs has raised $198 million after pricing its upsized U.S. initial public offering at the midpoint of the targeted range at $18 per share, the weight-loss drug developer said on Wednesday.
Weight-loss drug developer BioAge Labs aims to raise $198M from U.S. IPO
Weight-loss drug developer BioAge Labs (BIOA) on Wednesday announced the pricing of its upsized initial public offering of 11,000,000 shares of its common stock at a public offering price of $18.00 per share.
1d
Nasdaq Q3 Preview: Improving IPO Activity Could Start In H1 FY25
The acquisition of Adenza is expected to significantly boost Nasdaq's software revenue mix. Read why I maintain my strong buy ...
FierceBiotech
1d
BioAge brings in almost $200M from IPO as obesity biotech joins Nasdaq
BioAge Labs is bringing in almost $200 million via its Nasdaq IPO this morning, with the proceeds earmarked for taking its ...
57m
on MSN
Astera Labs Inc (NASDAQ:ALAB) Is One of the Top Underappreciated AI Stocks
We recently published a list of Top 10 Buzzing AI Stocks Now. Since Astera Labs Inc (NASDAQ:ALAB) ranks 10th on the list, it ...
1d
Cerebras Systems Eyes $7-8B Valuation in IPO
Cerebras Systems is targeting an IPO to raise up to $1 billion, potentially valuing the company at $7 billion to $8 billion. The company's CS-3 system is tailored to handle complex AI computing ...
1d
on MSN
BioAge stock rallies 29% following upsized $198M IPO
BioAge Labs (NASDAQ:BIOA) shares rallied nearly 30% Thursday after the obesity drug developer made its market debut through ...
1d
Investors Charge Up XCHG Stock In Scaled-Back IPO
Shares of XCHG nearly tripled in their first week of trading after the company raised $20.7 million in its Nasdaq IPO The ...
3d
Could CrowdStrike Stock Help You Become a Millionaire?
For now, it doesn't seem likely CrowdStrike can generate millionaire-making gains. It's still a decent play on the secular ...
NoCamels - Israeli Innovation News
2d
Ringing Nasdaq Bell, CyberArk Marks Decade Since IPO
CyberArk has marked the 10th anniversary of its initial public offering by ringing the opening bell at the Nasdaq Stock ...
2h
on MSN
Nasdaq, ICE get Outperform ratings at RBC in new exchange coverage
RBC assigned Outperform ratings to Nasdaq (NASDAQ:NDAQ) and Intercontinental Exchange (NYSE:ICE) and Sector Perform ratings ...
10h
on MSN
Kiran Mazumdar-Shaw's niece makes debut at Nasdaq with Bicara: ‘Bursting with pride’
Shaw's niece Claire Mazumdar's company Bicara Therapeutics made its debut at Nasdaq. For the ringing of the opening bell at ...
Hosted on MSN
5h
Biocon Founder Kiran Mazumdar-Shaw Celebrates Niece's Bicara Therapeutics Nasdaq Debut
Biocon founder and Chairperson Kiran Mazumdar-Shaw expressed her pride and joy on Wednesday as her niece, Claire Mazumdar, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
BioAge Labs
Initial public offering
FBS
Feedback